| R03AL03 |
Umeclidinium Bromide, Vilanterol |
ANORO ELLIPTA |
Inhalation powder, pre dispensed |
55 mcg/22 |
mcg |
1 inhaler (30 doses) |
GlaxoSmithKline (Ireland) Limited, Ирландия |
1 |
UD |
88.92 |
2.964 |
88.92 |
100% |
|
Съгласно РУ |
НСР-7453/10.11.2015.; НСР-9960/29.07.2016; НСР-12818/26.05.2017 г.; НСР-16690/30.08.2018; НСР-18473/22.04.2019 |
02.06.2019 |
|
Активен |
4097 |
| R03AL04 |
Indacaterol / Glycopyrronium bromide |
R03AL04 Indacaterol / Glycopyrronium bromide |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| R03AL04 |
Indacaterol and glycopyrronium bromide |
Ultibro Breezhaler |
Inhalation powder, hard capsule |
85 mcg /43 mcg |
|
30 x 1 capsules (unit dose) + 1 inhaler |
Novartis Europharm Limited, Ирландия |
1 |
UD (= 1 dose inhalation powder) |
88.61 |
2.65453 |
79.64 |
100% |
|
Съгласно РУ |
НСР-4636/15.09.2014; НСР-6138/29.04.2015.; НСР-11345/30.12.2016; Протокол 244/28.09.2017; НСР-14186/13.10.2017; НСР-15740/25.05.2018; НСР-16615/24.08.2018; НСР-17887/07.02.2019 |
02.04.2019 |
|
Активен |
3857 |
| R03AL05 |
Aclidinum bromide, Formoterol |
R03AL05 Aclidinum bromide, Formoterol |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| R03AL05 |
Aclidinum bromide, Formoterol |
Brimica Genuair |
Inhalation powder |
340 mcg/12 mcg |
mcg |
1 inhaler with 60 actuations |
Astra Zeneca AB, Швеция |
2 |
UD |
89.22 |
2.974 |
89.22 |
100% |
|
Съгласно РУ |
НСР-14441/17.11.2017 |
02.01.2018 |
|
Активен |
15934 |
| R03AL05 |
Aclidinum bromide, Formoterol |
Duaklir Genuair |
Inhalation powder |
340 mcg/12 mcg |
mcg |
1 inhaler with 60 actuations |
Astra Zeneca AB, Швеция |
2 |
UD |
89.24 |
2.974 |
89.22 |
100% |
|
Съгласно РУ |
НСР-11253/16.12.2016 (допуска се предварително изпълнение); НСР-13783/12.09.2017 |
02.01.2018 |
|
Активен |
15519 |
| R03AL06 |
Tiotropium bromide, Olodaterol |
R03AL06 Tiotropium bromide, Olodaterol |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| R03AL06 |
Tiotropium bromide, Olodaterol |
Spiolto Respimat |
Inhalation solution |
2,5 mcg/2,5 mcg |
|
Single pack: 1 Respimat inhaler and 1 cartridge, providing 60 puffs (30 medicinal doses) |
Boehringer Ingelheim International GmbH, Германия |
2 |
UD |
82.74 |
2.758 |
82.74 |
100% |
|
Съгласно РУ |
НСР-11252/16.12.2016 г. (предварително изпълнение); НСР-13795/12.09.2017; НСР-15684/17.05.2018; НСР-17850/31.01.2019 предварително изпъленение |
02.02.2019 |
|
Активен |
15523 |
| R03AL08 |
Fluticasone furoate, umeclidinium, vilanterol |
R03AL08 Fluticasone furoate, umeclidinium, vilanterol |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| R03AL08 |
Fluticasone furoate, umeclidinium, vilanterol |
Trelegy Ellipta |
Inhalation powder, pre dispensed |
92 mcg/55 mcg/22 mcg |
|
1 inhaler (30 doses) |
GlaxoSmithKline Trading Services Limited, Ирландия |
1 |
UD |
119.36 |
3.579 |
107.37 |
100% |
|
Съгласно РУ |
НСР-18448/11.04.2019 |
02.05.2019 |
|
Активен |
16495 |
| R03BA01 |
Beclometasone |
R03BA01 Beclometasone |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| R03BA01 |
Beclometasone |
Ecobec 100 MCG Easi-Breathe |
Pressurised inhalation, solution |
100 mcg/dose - 200 doses |
mcg |
1 |
Teva Czech Industries s.r.o., Чешка република |
1.5 |
mcg |
26.57 |
1.11911 |
14.92 |
100% |
|
Съгласно РУ |
№35/21.08.2009; НСР-1804/25.11.2013; НСР-4307/05.08.2014; НСР-5554/29.01.2015. |
16.02.2015 |
08.09.2012 |
Заличен |
3123 |
| R03BA01 |
Beclometasone |
Ecobec 250 MCG Easi-Breathe |
Pressurised inhalation, solution |
250 mcg/dose - 200 doses |
mcg |
1 |
Teva Czech Industries s.r.o., Чешка република |
1.5 |
mcg |
37.3 |
1.11911 |
37.3 |
100% |
|
Съгласно РУ |
№35/21.08.2009; НСР-5072/21.11.2014; НСР-7130/24.09.2015 |
16.10.2015 |
08.09.2012 |
Заличен |
3354 |
| R03BA02 |
Budesonide |
R03BA02 Budesonide |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| R03BA02 |
Budesonide |
BUDIAIR JET |
Pressurised inhalation, solution |
0,2 mg/dose - 200 doses |
|
1 |
Chiesi Farmaceutici SpA, Италия |
1.5 |
mg |
22.04 |
0.8264 |
22.04 |
100% |
|
Съгласно РУ |
КЦРР-475/19.04.2012 г.; НСР-3957/30.06.2014; НСР-11908/06.03.2017; НСР-13983/25.09.2017 |
02.11.2017 |
08.09.2012 |
Заличен |
2980 |
| R03BA02 |
Budesonide |
BUDIAIR MDI |
Pressurised inhalation, solution |
0,2 mg/dose - 200 doses |
mg |
1 |
Chiesi Farmaceutici SpA, Италия |
1.5 |
mg |
30.92 |
1.1595 |
30.92 |
100% |
|
Съгласно РУ |
КЦРР-475/19.04.2012 г.; КЦРР-2342/21.02.2013. |
04.04.2013 |
08.09.2012 |
Заличен |
1186 |
| R03BA02 |
Budesonide |
R03BA02 Budesonide |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| R03BA02 |
Budesonide |
Pulmicort Turbuhaler |
Inhalation powder |
200 micrograms/dose (100 doses) |
mg |
1 |
Astra Zeneca AB, Швеция |
0.8 |
mg |
14.98 |
0.5992 |
14.98 |
100% |
|
Съгласно РУ |
НСР-2120/14.12.2013; НСР-12384/18.04.2017 |
02.06.2017 |
|
Активен |
2353 |
| R03BA05 |
Fluticasone propionate |
R03BA05 Fluticasone propionate |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| R03BA05 |
Fluticasone |
Arquist |
Pressurised inhalation, suspension |
250 mcg/dose - 120 doses |
mcg |
1 |
S&D Pharma CZ spoI. s.r.o., Чешка република |
1.5 |
mg |
29.88 |
1.494 |
29.88 |
100% |
|
Съгласно РУ |
НСР-14170/13.10.2017; НСР-17524/13.12.2018 |
02.01.2019 |
|
Активен |
15903 |
| R03BA05 |
Fluticasone |
FLIXOTIDE 250 INHALER |
Pressurised inhalation, suspension |
250 mcg/dose x 60 doses |
mg |
1 |
Софарма АД, България |
1.5 |
mg |
33.23 |
1.494 |
14.94 |
100% |
|
Съгласно РУ |
|
02.01.2019 |
08.09.2012 |
Активен |
156 |
| R03BA05 |
Fluticasone |
FLIXOTIDE 50 INHALER |
Pressurised inhalation, suspension |
50 mcg/dose - 120 doses |
mg |
1 |
Софарма АД, България |
1.5 |
mg |
12.18 |
1.494 |
5.98 |
100% |
|
Съгласно РУ |
НСР-16709/30.08.2018 |
02.01.2019 |
08.09.2012 |
Активен |
157 |
| R03BA08 |
Ciclesonide |
R03BA08 Ciclesonide |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| R03BA08 |
Ciclesonide |
Alvesco |
Pressurised inhalation, solution |
160 mcg/dose - 60 metered actuations (дозирани впръсквания) |
mg |
1 |
Astra Zeneca AB, Швеция |
1 |
mg |
34.08 |
3.55 |
34.08 |
100% |
|
Съгласно РУ |
№ 25/03.08.2009; НСР-2922/07.03.2014; НСР-4923/22.10.2014; НСР-11282/22.12.2016 г.; НСР-15249/15.03.2018 |
02.04.2018 |
08.09.2012 |
Активен |
3274 |
| R03BB(04;05;06) |
Anticholinergics |
R03BB(04;05;06) Anticholinergics |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|